Skip to main content
. 2024 Oct 28;10:454. doi: 10.1038/s41420-024-02220-y

Fig. 8. Xanthohumol overcomes osimertinib resistance in NSCLC cells in vitro and in vivo.

Fig. 8

Administration of xanthohumol, osimertinib, or combination treatment in HCC827OR and H1975OR cells. Cell viability was analyzed by MTS assay (A); colony forming ability was analyzed by soft agar clone formation assay (B); caspase 3 activity was detected by caspase 3 activity assay kit (C); IB method to analyze c-Caspase 3 protein expression level (D). Scale bar, 200 μm. ***p < 0.001. A xenograft tumor model was constructed using HCC827OR cells, and mice were given xanthohumol, osimertinib, or co-treatment to examine the anti-tumor effects. The volume was recorded (E), the expression of Ki67 and c-Met in tumor tissues was examined (F), and the survival time of mice was recorded (G). Scale bar, 25 μm. ***p < 0.001.